kabutan

KAKEN PHARMACEUTICAL CO.,LTD.(4521) Summary

4521
TSE Prime
KAKEN PHARMACEUTICAL CO.,LTD.
4,010
JPY
+70
(+1.78%)
Dec 15, 3:30 pm JST
25.87
USD
Dec 15, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
66.0
PBR
1.03
Yield
4.74%
Margin Trading Ratio
6.68
Stock Price
Dec 15, 2025
Opening Dec 15, 9:00 am
3,955 JPY 25.37 USD
Previous Close Dec 12
3,940 JPY 25.29 USD
High Dec 15, 3:07 pm
4,020 JPY 25.92 USD
Low Dec 15, 9:00 am
3,950 JPY 25.34 USD
Volume
195,700
Trading Value
0.78B JPY 5.04M USD
VWAP
3993.37 JPY 25.76 USD
Minimum Trading Value
401,000 JPY 2,587 USD
Market Cap
0.18T JPY 1.14B USD
Number of Trades
560
Liquidity & Number of Trades
As of Dec 15, 2025
Liquidity
Slightly High
1-Year Average
650
1-Year High Apr 9, 2025
2,521
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 25,000 90,600 3.62
Nov 28, 2025 35,200 90,300 2.57
Nov 21, 2025 41,300 120,800 2.92
Nov 14, 2025 49,700 162,800 3.28
Nov 7, 2025 24,000 127,800 5.33
Company Profile
KAKEN PHARMACEUTICAL CO.,LTD. is a mid-sized pharmaceutical company. Its main products include joint function improvement agents and onychomycosis medications. The company also develops generic drugs and agricultural chemicals.
Sector
Pharmaceuticals
KAKEN PHARMACEUTICAL CO.,LTD. primarily engages in the pharmaceutical business, manufacturing and selling pharmaceuticals, medical devices, and agricultural chemicals. The company operates as a group that includes itself and two consolidated subsidiaries. In the pharmaceutical segment, Kaken Pharma and Asam handle manufacturing and sales. Additionally, the company is involved in the real estate business. The group as a whole focuses on the medical field while diversifying into areas such as agriculture. As a mid-sized player in the pharmaceutical industry, KAKEN PHARMACEUTICAL CO.,LTD. has established a unique product lineup and business structure, with its main products including the joint function improvement agent "ARTZ" and the onychomycosis treatment "Clenafin."